Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards remains the dominant force in ... The robust growth of transcatheter aortic valve replacement, or TAVR, has slowed as the category has become bigger and the patient pool more fully penetrated.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

Edwards Lifesciences Corporation (NYSE:EW) holds around 50% market share in the $7 billion transcatheter aortic valve replacement (TAVR) market. Its products in the sector are responsible for ...

Edwards Lifesciences Corp Larry Wood; Corporate Vice President - Transcatheter Aortic Valve Replacement; Edwards Lifesciences Corp Greetings, and welcome to the Edwards Lifesciences Corporation fourth ...

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

Edwards Lifesciences reported better-than-expected fourth-quarter sales, driven by its transcatheter aortic valve replacement (TAVR) devices, to finish 2024 on an upbeat but cautious note after a ...

On Tuesday, Edwards Lifesciences EW reported ... compared to analysts’ estimate of 55 cents. Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion ...